Ro 24-7429

Ro 24-7429 is a small molecule benzodiazepine derivative developed as an orally active antagonist of the HIV transactivator protein Tat and as an inhibitor of runt-related transcription factor 1 (RUNX1). It was originally investigated for its anti-HIV activity but showed no significant antiviral effect in clinical trials. More recently, it has demonstrated antifibrotic and anti-inflammatory effects in preclinical models by inhibiting RUNX1-mediated pathways. The drug was initially developed by F. Hoffmann-La Roche for HIV infection and later explored for potential use in fibrotic diseases such as pulmonary fibrosis[1][4][5][10].

Other names

7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amineUNII-MLW2GKK8LIUNII-MLW-2GKK8LIUNII-MLW 2GKK8LI